Claims for Patent: 10,016,404

Summary for Patent: 10,016,404

Title:	Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects
Abstract:	The present invention provides methods and compositions for treating hyperlipidemia and/or hypercholesterolemia comprising administering to the subject an effective amount of an MTP inhibitor to inhibit hyperlipidemia and/or hypercholesterolemia in said subject, wherein said administration comprises an escalating series of doses of the MTP inhibitor. In some embodiments the method comprises administering at least three step-wise, increasing dosages of the MTP inhibitor to the subject. In some embodiments, the method further comprises the administration of one or more other lipid modifying compounds.
Inventor(s):	Rader; Daniel J. (Philadelphia, PA)
Assignee:	The Trustees of the University of Pennsylvania (Philadelphia, PA)
Application Number:	15/605,548
Patent Claims:	1. A method of treating a human subject suffering from hyperlipidemia or hypercholesterolemia, the method comprising administering to the human subject an effective amount of an MTP inhibitor, the administration of the MTP inhibitor comprising three step-wise, increasing dose levels of the MTP inhibitor, wherein each of the dose levels is no more than 50% of the immediately following dose level; wherein each of the dose levels is administered for about 1 to about 12 weeks; wherein the MTP inhibitor is N-(2,2,2-trifluoroethyl)-9-[4-[4-[[[4' (trifluoromethyl)[1,1'-biphenyl]-2-yl] carbonyl] amino]-1-piperidinyl]butyl]-9H-fluorene-9 carboxamide, methanesulfonate; and wherein the administration of the MTP inhibitor reduces total cholesterol of the human subject by at least 30% as compared to control blood levels. 2. The method of claim 1, wherein the human subject suffering from hyperlipidemia or hypercholesterolemia has homozygous familial hypercholesterolemia. 3. The method of claim 1, wherein the administration of the MTP inhibitor further comprises a fourth dose level, and wherein the third dose level is no more than 50% of the fourth dose level. 4. The method of claim 1, wherein the administration of the MTP inhibitor reduces non-high- density lipoprotein cholesterol of the human subject by at least 30% as compared to control blood levels. 5. The method of claim 1, wherein the administration of the MTP inhibitor minimizes side effects as compared to administration of the MTP inhibitor to a human subject at a starting dose of 25 mg/day. 6. The method of claim 5, wherein the side effects minimized by the administration of the MTP inhibitor comprise an increase in liver transaminases, an increase in hepatic fat, or a combination thereof. 7. A method of treating a human subject suffering from hyperlipidemia or hypercholesterolemia, the method comprising administering to the human subject an effective amount of an MTP inhibitor, the administration of the MTP inhibitor comprising three step-wise, increasing dose levels of the MTP inhibitor, wherein each of the dose levels is no more than 50% of the immediately following dose level; wherein each of the dose levels is administered for about 1 to about 12 weeks; wherein the MTP inhibitor is N-(2,2,2-trifluoroethyl)-9-[4-[4-[[[4' (trifluoromethyl)[1,1'-biphenyl]-2-yl] carbonyl] amino]-1-piperidinyl]butyl]-9H-fluorene-9 carboxamide, methanesulfonate; and wherein the administration of the MTP inhibitor minimizes side effects as compared to administration of the MTP inhibitor to a human subject at a starting dose of 25 mg/day. 8. The method of claim 7, wherein the human subject suffering from hyperlipidemia or hypercholesterolemia has homozygous familial hypercholesterolemia. 9. The method of claim 7, wherein the administration of the MTP inhibitor further comprises a fourth dose level, and wherein the third dose level is no more than 50% of the fourth dose level. 10. The method of claim 7, wherein the administration of the MTP inhibitor reduces non-high- density lipoprotein cholesterol of the human subject by at least 30% as compared to control blood levels. 11. The method of claim 7, wherein the side effects minimized by the administration of the MTP inhibitor comprise an increase in liver transaminases, an increase in hepatic fat, or a combination thereof. 12. The method of claim 11, wherein the side effects minimized by the administration of the MTP inhibitor comprise an increase in hepatic fat. 13. The method of claim 12, wherein the increase in hepatic fat is not greater than 37% from baseline. 14. A method of treating a human subject suffering from hyperlipidemia or hypercholesterolemia, the method comprising administering to the human subject an effective amount of an MTP inhibitor, the administration of the MTP inhibitor comprising three step-wise, increasing dose levels of the MTP inhibitor, wherein each of the dose levels is no more than 50% of the immediately following dose level; wherein each of the dose levels is administered for about 1 to about 12 weeks; wherein the first dose level is sub-therapeutic; wherein the MTP inhibitor is N-(2,2,2-trifluoroethyl)-9-[4-[4-[[[4' (trifluoromethyl)[1,1'-biphenyl]-2-yl] carbonyl] amino]-1-piperidinyl]butyl]-9H-fluorene-9 carboxamide, methanesulfonate; and wherein the administration of the MTP inhibitor reduces total cholesterol of the human subject by at least 30% as compared to control blood levels. 15. The method of claim 14, wherein the human subject suffering from hyperlipidemia or hypercholesterolemia has homozygous familial hypercholesterolemia. 16. The method of claim 14, wherein the administration of the MTP inhibitor further comprises a fourth dose level, and wherein the third dose level is no more than 50% of the fourth dose level. 17. The method of claim 14, wherein the administration of the MTP inhibitor reduces non-high- density lipoprotein cholesterol of the human subject by at least 30% as compared to control blood levels. 18. The method of claim 14, wherein the administration of the MTP inhibitor minimizes side effects as compared to administration of the MTP inhibitor to a human subject at a starting dose of 25 mg/day. 19. The method of claim 18, wherein the side effects minimized by the administration of the MTP inhibitor comprise an increase in liver transaminases, an increase in hepatic fat, or a combination thereof. 20. A method of treating a human subject suffering from hyperlipidemia or hypercholesterolemia, the method comprising administering to the human subject an effective amount of an MTP inhibitor, the administration of the MTP inhibitor comprising three step-wise, increasing dose levels of the MTP inhibitor, wherein each of the dose levels is no more than 50% of the immediately following dose level; wherein each of the dose levels is administered for about 1 to about 12 weeks; wherein the first dose level is sub-therapeutic; wherein the MTP inhibitor is N-(2,2,2-trifluoroethyl)-9-[4-[4-[[[4' (trifluoromethyl)[1,1'-biphenyl]-2-yl] carbonyl] amino]-1-piperidinyl]butyl]-9H-fluorene-9 carboxamide, methanesulfonate; and wherein the administration of the MTP inhibitor minimizes side effects as compared to administration of the MTP inhibitor to a human subject at a starting dose of 25 mg/day. 21. The method of claim 20, wherein the human subject suffering from hyperlipidemia or hypercholesterolemia has homozygous familial hypercholesterolemia. 22. The method of claim 20, wherein the administration of the MTP inhibitor further comprises a fourth dose level, and wherein the third dose level is no more than 50% of the fourth dose level. 23. The method of claim 20, wherein the administration of the MTP inhibitor reduces non-high- density lipoprotein cholesterol of the human subject by at least 30% as compared to control blood levels. 24. The method of claim 20, wherein the side effects minimized by the administration of the MTP inhibitor comprise an increase in liver transaminases, an increase in hepatic fat, or a combination thereof. 25. The method of claim 24, wherein the side effects minimized by the administration of the MTP inhibitor comprise an increase in hepatic fat. 26. The method of claim 25, wherein the increase in hepatic fat is not greater than 37% from baseline.